We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

LGC Clinical Diagnostics

LGC Clinical Diagnostics is a leading provider of Quality Measurement Tools, biological materials, and reagents for t... read more Featured Products: More products

Download Mobile App




LGC Acquires German Quality Controls Maker DiaMex

By LabMedica International staff writers
Posted on 05 Dec 2024

LGC (London, UK) has made an addition to its growing global clinical diagnostics and genomics portfolio by acquiring DiaMex (Heidelberg, Germany), a manufacturer of third-party serology and molecular quality controls used in clinical laboratories and blood banks across the world. More...

DiaMex is known for delivering top-quality controls, with a proven track record of successful product development achieved through collaboration with strategic partners. Over the past 13 years, DiaMex has offered a comprehensive range of third-party serology controls to its customers, and more recently, has expanded its offerings to include the development and commercialization of molecular controls.

LGC is a global leader in life science tools, committed to collaborating with customers to provide solutions that address critical challenges in diagnosing, treating, feeding, and protecting the growing global population. With over 180 years of scientific expertise, LGC works alongside the scientific community to confront some of the world’s most complex problems, including global health crises, advancements in precision medicine, and improving the safety of food, medicines, and the environment. Operating in 14 countries, LGC’s products and services are essential to industries that ensure the safety of public health, food, water, and medicine. LGC’s solutions assist its diverse customer base—including pharmaceutical companies, diagnostic manufacturers, testing laboratories, and food producers—by helping them maintain the highest standards of quality, safety, and regulatory compliance.

“By acquiring DiaMex, we will now have access to a best-in-class product range (Optitrol) that complements our own quality control portfolio,” said Ken Yoon, Executive Vice President and General Manager of LGC’s Diagnostics & Genomics Business Unit. “This will greatly enhance the choice of products we can offer our customers within the core laboratory and blood bank spaces, helping us to drive stronger partnerships together, particularly for our clients in Europe, Asia Pacific, and Latin America.”

“As we continue to seek opportunities to strengthen the portfolio of in vitro diagnostics serology and molecular controls we can offer our clinical laboratory customers, we are delighted to welcome DiaMex to the LGC family,” added Bharathi Anekella, Executive Vice President and leader of LGC’s Diagnostics & Genomics Innovation Hub. “This acquisition will enable us to drive innovation forward much more rapidly and give us a highly differentiated product portfolio.”

Related Links:
LGC


Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit
New
Hemoglobin/Haptoglobin Assay
IDK Hemoglobin/Haptoglobin Complex ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.